---
title: Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects
nct_id: NCT05141110
overall_status: COMPLETED
phase: PHASE1
sponsor: NVP Healthcare
study_type: INTERVENTIONAL
primary_condition: Healthy Subjects
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05141110.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05141110"
ct_last_update_post_date: 2022-09-29
last_seen_at: "2026-05-12T06:54:33.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects

**Official Title:** A Phase 1 Clinical Trial, Open-label, Randomized Study in Healthy Subjects to Evaluate Pharmacokinetic Characteristics and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects

**NCT ID:** [NCT05141110](https://clinicaltrials.gov/study/NCT05141110)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** NVP Healthcare
- **Conditions:** Healthy Subjects
- **Start Date:** 2021-12-29
- **Completion Date:** 2022-06-29
- **CT.gov Last Update:** 2022-09-29

## Brief Summary

The purpose of this study is to compare the pharmacokinetics and safety of NVP-1705 and NVP-1705-R.

## Detailed Description

Evaluate the pharmacokinetics and safety of NVP-1705 compared to NVP-1705-R

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy subject, 19 years of age or older
* Subjects who signed informed consent
* Body mass index(BMI) of 18 to 30.0 kg/㎡

Exclusion Criteria:

* Subject who has clinically significant medical history
* Inadequate subject for the clinical trial by the investigator's decision
* Subjects participated in another clinical trial within 6 months prior to the first administration of investigational product
```

## Arms

- **NVP-1705** (EXPERIMENTAL) — Tablet formulation for oral administration, single dose of NVP-1705 at Day 1
- **NVP-1705-R** (ACTIVE_COMPARATOR) — Tablet formulation for oral administration, single dose of NVP-1705-R at Day 1

## Interventions

- **NVP-1705** (DRUG) — NVP-1705
- **NVP-1705-R** (DRUG) — NVP-1705-R

## Primary Outcomes

- **Evaluation of Area under the plasma drug concentration-time curve(AUCt)** _(time frame: 0 ~ 48 hours)_ — Pharmacokinetics parameter derived from plasma
- **Evaluation of Maximum observed plasma concentration(Cmax)** _(time frame: 0 ~ 48 hours)_ — Pharmacokinetics parameter derived from plasma

## Secondary Outcomes

- **Evaluation pf Area under the plasma drug concentration-time curve from time 0 to infinity(AUC∞)** _(time frame: 0 ~ 48 hours)_
- **Evaluation of AUCt/AUC∞** _(time frame: 0 ~ 48 hours)_
- **Evaluation of Time of peak concentration(Tmax)** _(time frame: 0 ~ 48 hours)_
- **Evaluation of Terminal phase of Half-life(t1/2)** _(time frame: 0 ~ 48 hours)_

## Locations (1)

- H Plus Yangji Hospital, Seoul, Nambusunhwan-ro, South Korea

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `locations.h plus yangji hospital|seoul|nambusunhwan-ro|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05141110.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05141110*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*